07:44 AM EDT, 08/08/2024 (MT Newswires) -- Royalty Pharma ( RPRX ) reported Q2 operating income Thursday of $270 million, up from $249 million a year earlier.

Three analysts polled by Capital IQ expected $474.4.

Revenue for the quarter ended June 30 was $537 million, down from $538 million a year earlier.

Three analysts surveyed by Capital IQ expected $645.3 million.

As of June 30, Royalty Pharma ( RPRX ) had cash and cash equivalents of $1.8 billion and total debt with a principal value of $7.8 billion.

Price: 26.86, Change: -0.39, Percent Change: -1.43